60 articles with Terumo Corporation
Diabeloop SA. and Terumo Corporation enter into joint development agreement with exclusive distribution right for DBLG1® automated insulin delivery solution in Japanese market
The French company Diabeloop, a pioneer in therapeutic AI, and Terumo Corporation, a global leader in medical technology, announced that they have signed an agreement for the joint development with exclusive distribution rights in Japan of an automated insulin delivery solution.
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
Thailand, with a Population of 70 million People, Joins Other Significant Territories Japan and Singapore That will Benefit From IceCure's Cryoablation Products
Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation, and CytoSorbents Corporation, manufacturer of the CytoSorb® extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S.
Terumo Corporation announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy, a treatment for liver tumors.
Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema.
Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon
Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions
Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed's Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership
First and only non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus
MicroVention Announces Positive Safety And Effectiveness Results In Web-It Pivotal Trial Published In Journal Of NeuroInterventional Surgery
The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.
Xenex Disinfection Services announced it has expanded its relationship with Terumo Corporation.
Medeon Biodesign, Inc. is pleased to announce today that it entered into a definitive asset purchase agreement with Tokyo-based Terumo Corporation for its large bore vascular closure system.
Terumo Chooses Xenex Lightstrike Germ-Zapping Robots To Disinfect Healthcare Facilities & Improve Patient Safety In Japan
OrbusNeich Announces Favorable Ruling From The European Patent Office And Initiation Of Litigation Against Terumo Corporation
Arterial Remodeling Technologies And Terumo Corporation: Promising Pre-Clinical Data On The Next Generation Drug Eluting Bioresorbable Scaffold